The real hope of overcoming the COVID-19 passes by the huge amount of work that is being done to arrive at the development of a vaccine. Research in the United Kingdom as well as in China raise even hope to achieve this goal by the end of the year.
“It’s going to take until at least the end of this year for the phase 3 studies will lead, and can be finished and analyzed. And possibly, it is necessary to proceed to the manufacture of vaccines. This is assuming that everything goes well”, relativizes the Dr. Cécile Tremblay, who is a microbiologist and infectious diseases physician at the CHUM.
Still, the most recent news is encouraging. Currently, 250 of research is conducted in the world to develop a vaccine and the results would be promising in the Uk, or scientists from Oxford University have conducted clinical trials on 1077 adults aged 18 to 55 years of age who have never been infected by the coronavirus.
Scientists have not found any serious side effects in the participants, and the vaccine has stimulated antibody production.
“They have demonstrated that there is an immune response that seems to be satisfactory. But between having antibodies and having a good protection, and sometimes, nature is full of surprises,” notes Dr. Gaston De Serres, epidemiologist at national Institute of public health of Quebec (INSPQ)
This pharmaceutical believes that the vaccine will be available by the end of 2020. Governments believe in it also and have booked a total of two billion doses.
During this time, in China, a pharmaceutical associated with a group of military research has administered a vaccine to 500 people, in clinical trials, and there would have been a great immune response. The vaccine chinese uses an adenovirus responsible for the common cold in humans, while the one manufactured in the United Kingdom uses the one that causes the common cold in monkeys.
“Adenoviruses are vectors that cause little disease in humans and in which one can insert the protein of the coronavirus that we want to present to the immune system,” explains Dr. Tremblay.
If the results are encouraging, we must now go further in the clinical trials.
“There must be tens of thousands of people, said Dr. De Serres. It is necessary that these people, some of them are infected by the disease so that you could see if among the vaccinated the risk is lower than in the non-vaccinated.”